Daily Stock Analysis, CGEN, Compugen Ltd, priceseries

Compugen Ltd. Daily Stock Analysis
Stock Information
Open
5.05
Close
5.05
High
5.05
Low
4.90
Previous Close
5.10
Daily Price Gain
-0.05
YTD High
5.40
YTD High Date
May 25, 2017
YTD Low
3.60
YTD Low Date
May 8, 2017
YTD Price Change
-0.05
YTD Gain
-0.98%
52 Week High
7.57
52 Week High Date
Sep 2, 2016
52 Week Low
3.60
52 Week Low Date
May 8, 2017
52 Week Price Change
-1.78
52 Week Gain
-26.06%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 27. 2015
6.55
Jun 9. 2015
7.34
9 Trading Days
12.00%
Link
LONG
Oct 13. 2015
5.59
Oct 29. 2015
6.17
12 Trading Days
10.36%
Link
LONG
Nov 13. 2015
6.72
Dec 3. 2015
7.43
13 Trading Days
10.59%
Link
LONG
Apr 6. 2016
6.13
Apr 28. 2016
6.76
16 Trading Days
10.25%
Link
LONG
Nov 7. 2016
6.05
Nov 18. 2016
6.44
9 Trading Days
6.40%
Link
Company Information
Stock Symbol
CGEN
Exchange
NasdaqGM
Company URL
www.cgen.com
Company Phone
011-972-3-765-8585
CEO
Anat Cohen-Dayag
Headquarters
-
Business Address
26 HAROKMIM STREET, BUILDING D, HOLON, ISRAEL 5885849
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001119774
About

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Description

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.